Plain-English translation of NCT06892145 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a new treatment made from your own immune cells that have been engineered in the lab to target and calm down the cells causing lupus damage. The therapy is designed to be made quickly — in about 3 days — and given as a single infusion into your bloodstream. Researchers hope this approach will help people whose lupus hasn't improved with standard medications.
Some people with lupus don't respond well enough to the current standard treatments, and their disease continues to cause serious damage. This medication offers a completely different approach by retraining the immune system itself, which may help when other options haven't worked.
You likely qualify if…
You likely don't qualify if…
You would have blood drawn or undergo apheresis to collect your immune cells, which would then be sent to the lab for engineering (taking about 3 days). Once ready, you would return to receive a single infusion of the engineered cells. After that, you would be monitored closely with blood tests and clinic visits to track how the treatment is working and watch for any side effects. The trial will follow you over time to see whether the medication helps control your lupus and how long the benefit lasts.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China